Protein HLJ1 slowing the progression lung cancer

An investigation identified a protein that may curb lung cancer. HLJ1 protein is involved in slowing the progression of lung cancer, the researchers said.
Scientists at the National Taiwan University (China) have concluded that a protein called HLJ1 could function as tumor suppressor in non-small cell lung cancer.

The study, published in the Journal of the National Cancer Institute was based on increasing or blocking HLJ1 expression in lung carcinoma cells, and gene expression observed in tumors and adjacent tissue cells in 71 patients with cancer NSCLC.

Stanford bans gifts from drug companies, including pens

Medical Center Stanford University banned their doctors accept gifts (including children) from representatives of pharmaceutical companies, under a new policy that seeks to limit industry influence on patient care and medical education.

The new rules, to be announced today, are part of a growing trend among academic medical centers. Yale and the University of Pennsylvania, for example, have announced similar policies.

Melanoma vaccine

Hundred percent development argentinoUna melanoma vaccine ready for final test Will be tested in 108 patients with skin cancer, would be available in 3 or 4 years.

Argentine researchers have developed a vaccine to treat melanoma, the most common form of cancer in people aged between 15 and 44 years will begin in the coming months with phase studies in patients prior to approval by authorities local regulatory. If you pass this last test, called Vaccimel vaccine could be available in 3 to 4 years. "After three years of receiving the vaccine, 70% of patients in advanced stages of melanoma who participated in clinical studies so far remained free of disease," said Dr. Marcela Barrio, CONICET researcher involved in the development of Vaccimel, during a press conference held in Expo-Medical.